Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial
Introduction The observed alteration of the intestinal microbiota in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the effect of transferring a healthy gut flora from a faecal donor using a faecal microbiota transplantation (FMT) will be explored in this trial. Method...
Published in: | BMJ Open |
---|---|
Main Authors: | , , , |
Other Authors: | , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMJ
2024
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1136/bmjopen-2023-073275 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2023-073275 |
id |
crjcrbmj:10.1136/bmjopen-2023-073275 |
---|---|
record_format |
openpolar |
spelling |
crjcrbmj:10.1136/bmjopen-2023-073275 2024-06-23T07:55:34+00:00 Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial Skjevling, Linn Goll, Rasmus Hanssen, Hege Marie Johnsen, Peter Holger Norges Forskningsråd The Norwegian patient organization for ME/CFS 2024 http://dx.doi.org/10.1136/bmjopen-2023-073275 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2023-073275 en eng BMJ http://creativecommons.org/licenses/by-nc/4.0/ BMJ Open volume 14, issue 6, page e073275 ISSN 2044-6055 2044-6055 journal-article 2024 crjcrbmj https://doi.org/10.1136/bmjopen-2023-073275 2024-06-13T04:15:24Z Introduction The observed alteration of the intestinal microbiota in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the effect of transferring a healthy gut flora from a faecal donor using a faecal microbiota transplantation (FMT) will be explored in this trial. Methods and analysis This is a protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial, with 12 months follow-up. 80 participants will be included and randomised (1:1:2) to either donor FMT (from two different donors) or placebo (autologous FMT). Participants will be included by the International Clinical Criteria for ME/CFS. The clinical measures of ME/CFS and disease activity include Modified DePaul Questionnaire, Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), 36-Item Short Form Health Survey (SF-36), ROMA IV criteria, Food Frequency Questionnaire, Repeatable Battery for the Assessment of Neuropsychological Status, heart rate variability testing and reports on the use of antibiotics and food supplements, as well as biobanking of blood, urine and faeces. The primary endpoint is proportion with treatment success in FSS score in donor versus autologous FMT group 3 months after treatment. Treatment success is defined as an FSS improvement of more than 1.2 points from baseline at 3 months after treatment. Adverse events will be registered throughout the study. Ethics and dissemination The Regional Committee for Medical Research Ethics Northern Norway has approved the study. The study has commenced in May 2019. Findings will be disseminated in international peer-reviewed journal(s), submitted to relevant conferences, and trial participants will be informed via phone calls. Trial registration number NCT03691987 . Article in Journal/Newspaper Northern Norway The BMJ Norway BMJ Open 14 6 e073275 |
institution |
Open Polar |
collection |
The BMJ |
op_collection_id |
crjcrbmj |
language |
English |
description |
Introduction The observed alteration of the intestinal microbiota in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the effect of transferring a healthy gut flora from a faecal donor using a faecal microbiota transplantation (FMT) will be explored in this trial. Methods and analysis This is a protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial, with 12 months follow-up. 80 participants will be included and randomised (1:1:2) to either donor FMT (from two different donors) or placebo (autologous FMT). Participants will be included by the International Clinical Criteria for ME/CFS. The clinical measures of ME/CFS and disease activity include Modified DePaul Questionnaire, Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), 36-Item Short Form Health Survey (SF-36), ROMA IV criteria, Food Frequency Questionnaire, Repeatable Battery for the Assessment of Neuropsychological Status, heart rate variability testing and reports on the use of antibiotics and food supplements, as well as biobanking of blood, urine and faeces. The primary endpoint is proportion with treatment success in FSS score in donor versus autologous FMT group 3 months after treatment. Treatment success is defined as an FSS improvement of more than 1.2 points from baseline at 3 months after treatment. Adverse events will be registered throughout the study. Ethics and dissemination The Regional Committee for Medical Research Ethics Northern Norway has approved the study. The study has commenced in May 2019. Findings will be disseminated in international peer-reviewed journal(s), submitted to relevant conferences, and trial participants will be informed via phone calls. Trial registration number NCT03691987 . |
author2 |
Norges Forskningsråd The Norwegian patient organization for ME/CFS |
format |
Article in Journal/Newspaper |
author |
Skjevling, Linn Goll, Rasmus Hanssen, Hege Marie Johnsen, Peter Holger |
spellingShingle |
Skjevling, Linn Goll, Rasmus Hanssen, Hege Marie Johnsen, Peter Holger Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial |
author_facet |
Skjevling, Linn Goll, Rasmus Hanssen, Hege Marie Johnsen, Peter Holger |
author_sort |
Skjevling, Linn |
title |
Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial |
title_short |
Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial |
title_full |
Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial |
title_fullStr |
Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial |
title_full_unstemmed |
Faecal microbiota transplantation (FMT) in Norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): protocol for a 12-month randomised double-blind placebo-controlled trial |
title_sort |
faecal microbiota transplantation (fmt) in norwegian outpatients with mild to severe myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs): protocol for a 12-month randomised double-blind placebo-controlled trial |
publisher |
BMJ |
publishDate |
2024 |
url |
http://dx.doi.org/10.1136/bmjopen-2023-073275 https://syndication.highwire.org/content/doi/10.1136/bmjopen-2023-073275 |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Northern Norway |
genre_facet |
Northern Norway |
op_source |
BMJ Open volume 14, issue 6, page e073275 ISSN 2044-6055 2044-6055 |
op_rights |
http://creativecommons.org/licenses/by-nc/4.0/ |
op_doi |
https://doi.org/10.1136/bmjopen-2023-073275 |
container_title |
BMJ Open |
container_volume |
14 |
container_issue |
6 |
container_start_page |
e073275 |
_version_ |
1802648204289769472 |